Portland, OR -- (SBWIRE) -- 08/31/2017 -- Human microbiome drugs and diagnostics basically involves the use of microorganisms of human body for the treatment of diseases. The modern approach involves exploiting the interaction between humans and the bacteria that live in or on the body to develop new drugs and therapies to treat chronic diseases such as diabetes. These microbiomes derived drugs help the physician in better diagnosis of the illness. The emergence of healthcare cum technology devices have addressed the increasing needs for better therapeutics. The technologically advanced human microbiome drugs and diagnostics have surmounted the conventional methods in terms of reducing the side effects caused due to the excessive use of antibiotics.

For Sample PDF - Click Here@ https://www.alliedmarketresearch.com/request-toc-and-sample/1530

Rising cases of chronic diseases such as diabetes, disorders at early stage and the ability of the drugs to diagnose them and increased awareness among people to maintain healthy lifestyle is driving the growth of this market. Besides, rise in geriatric population, increasing expenditure on healthcare and growing demand for effective procedures and safe medication are expected to further fuel the market growth. However, lack of awareness about the health benefits of probiotics and prebiotics coupled with unfavorable government regulations have restricted the growth of the market in developing regions.

Contemplating its segmentation, the market is divided on the basis of product, application, disease, and geography. On the basis of research spending market, human microbiome is segmented by product and technology type. By product, market is segmented into food, probiotics, prebiotics, medical food, diagnostic devices, drugs and other probiotic supplements. The human microbiome based drugs and diagnostics market is segmented on the grounds of application type into therapeutics and diagnostics. On the basis of disease market is divided into acute diarrhea, obesity, diabetes, autoimmune disorders, cancer, mental disorders and other diseases.

Strategies such as collaboration and agreement have been adopted by the companies for market growth. Enterome signed an agreement with Vertex pharmaceuticals Inc. (April 2016) to develop small molecules FimH anatgonists to treat inflammatory bowel disease. Besides, Second genome and Mayo clinic entered a partnership (October 2014) to develop therapeutics products for microbiome mediated pathways.

HUMAN MICROBIOME BASED DRUGS AND DIAGNOSTICS MARKET SEGMENTS:

By Product

- Food
- Probiotics
- Prebiotics
- Medical Food
- Diagnostic Devices
- Drugs

Access Full Summary of Report@ https://www.alliedmarketresearch.com/human-microbiome-based-drugs-and-diagnostics-market

By Application

- Therapeutics
- Diagnostics

By Disease

- Acute Diarrhea
- Obesity
- Diabetes
- Autoimmune Disorders
- Cancer
- Mental Disorders

By Research Spending, Product Type

- Instruments
- Consumables

By Research Spending, Technology Type

- Cell Culture Technology
- High Throughput Technology
- Omics Technology
- Computational Tools